Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
Annelisa M. Cornel, Ester Dünnebach, Damon A. Hofman, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005002-e005002
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy
Judith Wienke, Lindy L. Visser, Waleed M. Kholosy, et al.
Cancer Cell (2024)
Open Access | Times Cited: 34
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
Wan Ching Lim, Maria Eugénia Marques Da Costa, Karine Godefroy, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 5
Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy
Di Chen, Lixia Xu, Mengjuan Xuan, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 9
Open Access | Times Cited: 4
PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma
Xiao Zhang, Kaijun Sun, Bingzheng Zhong, et al.
Clinical & Translational Oncology (2025)
Closed Access
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis
Chenyue Wang, Lisha Wu, Xingxing Li, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e009621-e009621
Open Access
Harnessing Histone Deacetylase Inhibitors for Enhanced Cancer Immunotherapy
Fatemeh Hedayat, Elnaz Faghfuri
European Journal of Pharmacology (2025) Vol. 997, pp. 177620-177620
Closed Access
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG
Yuxuan Deng, Jinqiu Liu, Zhuonan Pu, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Organoid co‐culture models of the tumor microenvironment promote precision medicine
Zhaoru Gu, Quanyou Wu, Bingqing Shang, et al.
Cancer Innovation (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 9
The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy
Zhixiang Hu, Xinyi Guo, Ziteng Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189126-189126
Closed Access | Times Cited: 3
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma
Patrizia Tempora, Silvia D’Amico, Paula Gragera, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 3
Natural killer cells at the forefront of cancer immunotherapy with immune potency, genetic engineering, and nanotechnology
Weiyi Pan, Tao Tao, Yishu Qiu, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104231-104231
Closed Access | Times Cited: 9
Preclinical Models of Neuroblastoma—Current Status and Perspectives
Ewa Krawczyk, Joanna Kitlińska
Cancers (2023) Vol. 15, Iss. 13, pp. 3314-3314
Open Access | Times Cited: 7
Strategies to overcome low MHC-I expression in paediatric and adult tumours
Joël Guillaume, Alicia Perzolli, Marianne Boes
Immunotherapy Advances (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 5
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1
Annelisa M. Cornel, Loutje van der Sman, Jip T. van Dinter, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007538-e007538
Open Access | Times Cited: 1
Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma
Shuping Yang, Zhi Li, Jiamei Yi, et al.
Anti-Cancer Drugs (2024)
Open Access | Times Cited: 1
Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer
Wenqian Dong, Bing He, Yanhong Cao, et al.
Cellular Oncology (2024) Vol. 48, Iss. 1, pp. 249-264
Open Access | Times Cited: 1
Epigenetic therapies for neuroblastoma: immunogenicity awakens
Carlos Jiménez, Lucas Moreno, Miguel F. Segura
Molecular Oncology (2023) Vol. 17, Iss. 5, pp. 718-721
Open Access | Times Cited: 3
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges
Elisa Zappa, Alice Vitali, Kathleen Anders, et al.
European Journal of Cancer (2023) Vol. 194, pp. 113347-113347
Open Access | Times Cited: 3
Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity
Silvia D’Amico, Patrizia Tempora, Paula Gragera, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
PRMT5 orchestrates EGFR and AKT networks to activate NFκB and promote EMT
Lei Huang, Manasa Ravi, Xiao‐Ou Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Immunotherapy Options for Neuroblastoma: What is on the Horizon?
Aysima Karakus, Beyda Berberogullari
Current Molecular Biology Reports (2024) Vol. 10, Iss. 3, pp. 43-53
Closed Access
Advances in the approaches used to repurpose drugs for neuroblastoma
Marta Miera-Maluenda, María Pérez-Torres, Adriana Mañas, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 11, pp. 1309-1319
Closed Access
The triad in current neuroblastoma challenges: Targeting antigens, enhancing effective cytotoxicity and accurate 3D in vitro modelling
Ellen Eva King, Ronja Struck, Olga Piskareva
Translational Oncology (2024) Vol. 51, pp. 102176-102176
Closed Access
Exploring the Role of Fibroblasts in Promoting Neuroblastoma Cell Migration and Invasion
Diana Corallo, C. Nardelli, Marcella Pantile, et al.
Journal of Nanotheranostics (2024) Vol. 5, Iss. 4, pp. 212-227
Open Access
Page 1 - Next Page

Scroll to top